PVLA vs. WVE, ABCL, DYN, ELVN, AUPH, ARDX, VERV, NAGE, COLL, and AKBA
Should you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include WAVE Life Sciences (WVE), AbCellera Biologics (ABCL), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Collegium Pharmaceutical (COLL), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.
Palvella Therapeutics vs. Its Competitors
WAVE Life Sciences (NASDAQ:WVE) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.
WAVE Life Sciences currently has a consensus price target of $20.50, indicating a potential upside of 194.12%. Palvella Therapeutics has a consensus price target of $46.29, indicating a potential upside of 91.90%. Given WAVE Life Sciences' higher probable upside, research analysts plainly believe WAVE Life Sciences is more favorable than Palvella Therapeutics.
Palvella Therapeutics' return on equity of -60.29% beat WAVE Life Sciences' return on equity.
WAVE Life Sciences has a beta of -1.01, meaning that its share price is 201% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500.
In the previous week, Palvella Therapeutics had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Palvella Therapeutics and 2 mentions for WAVE Life Sciences. Palvella Therapeutics' average media sentiment score of 0.87 beat WAVE Life Sciences' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.
89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 29.1% of WAVE Life Sciences shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Palvella Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Palvella Therapeutics beats WAVE Life Sciences on 8 of the 15 factors compared between the two stocks.
Get Palvella Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palvella Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PVLA) was last updated on 7/4/2025 by MarketBeat.com Staff
Free PVLA Stock Alerts